Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker PRAX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in… NCT06087276 · Essential Tremor 60 mg ulixacaltamide, Placebo | PRAX Praxis Precision Medicines | Phase 3 | Recruiting | 1,000 | Oct 10, 2025 | Registry ↗ |
| Aug 10, 2026 | Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and S… NCT06999902 · Focal Seizure 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for re… | PRAX Praxis Precision Medicines | Phase 2/3 | Completed | 255 | May 14, 2026 | Registry ↗ |
| Aug 4, 2026 | A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relu… NCT07010471 · Developmental and Epileptic Encephalopathy 1 1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX-562 | PRAX Praxis Precision Medicines | Phase 3 | Active, not recruiting | 160 | Dec 2026 | Registry ↗ |
| Aug 3, 2026 | Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal S… NCT07505004 · Focal Epilepsy 40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine… | PRAX Praxis Precision Medicines | Phase 3 | Active, not recruiting | 300 | Jan 2027 | Registry ↗ |
| Aug 3, 2026 | Clinical Trial of Vormatrigine in Adult Patients With Epilepsy NCT07287163 · Epilepsy, Tonic-Clonic, Focal Seizure vormatrogine | PRAX Praxis Precision Medicines | Phase 3 | Enrolling by invitation | 700 | May 31, 2028 | Registry ↗ |
| Aug 3, 2026 | A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety NCT07019922 · Epileptic Encephalopathy, SCN2A Encephalopathy 1mg elsunersen, 0.5mg elsunersen | PRAX Praxis Precision Medicines | Phase 3 | Recruiting | 40 | Dec 2026 | Registry ↗ |
| Aug 3, 2026 | A Clinical Trial to Evaluate the Relative Bioavailability of PRAX-628 NCT06840925 · Healthy PRAX-628 | PRAX Praxis Precision Medicines | Phase 1 | Completed | 16 | Jun 5, 2025 | Registry ↗ |
| Aug 3, 2026 | A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epi… NCT05737784 · SCN2A-DEE, Epilepsy PRAX-222 - Initial Dose, PRAX-222 - Initial Ascending Doses | PRAX Praxis Precision Medicines | Phase 1/2 | Active, not recruiting | 60 | Apr 1, 2026 | Registry ↗ |
| Jan 29, 2026 | A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE) NCT05818553 · SCN2A Encephalopathy, SCN8A Encephalopathy PRAX-562 | PRAX Praxis Precision Medicines | Phase 2/3 | Active, not recruiting | 77 | Nov 12, 2025 | Registry ↗ |
| Apr 3, 2025 | An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or T… NCT06908356 · Focal Onset Seizure, Primary Generalized Epilepsy 30mg PRAX-628 | PRAX Praxis Precision Medicines | Phase 2 | Recruiting | 50 | Jul 2025 | Registry ↗ |
| Mar 13, 2024 | A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor NCT05021991 · Essential Tremor 100 mg PRAX-944, 60 mg PRAX-944 | PRAX Praxis Precision Medicines | Phase 2 | Completed | 133 | Feb 9, 2023 | Registry ↗ |
| Mar 1, 2024 | A Clinical Trial of PRAX-944 in Participants With Essential Tremor NCT05021978 · Essential Tremor Part A: 20 and 40 mg PRAX-944, Part B: 120 mg PRAX-944 | PRAX Praxis Precision Medicines | Phase 2 | Completed | 24 | Mar 24, 2022 | Registry ↗ |
| Jan 10, 2024 | A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developm… NCT05407727 · SCN2A-DEE, Epilepsy | PRAX Praxis Precision Medicines | — | Completed | 5 | Mar 31, 2023 | Registry ↗ |
| Dec 1, 2022 | A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder NCT05260541 · Post-traumatic Stress Disorder, Post Traumatic Stress Disor… 60 mg PRAX-114 or 40 mg PRAX-114, Placebo | PRAX Praxis Precision Medicines | Phase 2 | Terminated | 11 | Aug 1, 2022 | Registry ↗ |
| Nov 30, 2022 | A Clinical Trial of PRAX-114 in Participants With Essential Tremor NCT05387642 · Essential Tremor 10 mg PRAX-114, 20 mg PRAX-114, and Placebo, 10 mg PRAX-114… | PRAX Praxis Precision Medicines | Phase 2 | Withdrawn | 0 | Jun 30, 2022 | Registry ↗ |
| Aug 19, 2022 | A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disor… NCT04969510 · Major Depressive Disorder 10 mg PRAX-114, 20 mg PRAX-114 | PRAX Praxis Precision Medicines | Phase 2 | Completed | 110 | Jul 15, 2022 | Registry ↗ |
| Jul 21, 2022 | A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder NCT04832425 · Major Depressive Disorder PRAX-114, Placebo | PRAX Praxis Precision Medicines | Phase 2/3 | Completed | 216 | May 5, 2022 | Registry ↗ |
17 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:50 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances